Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.
You may also be interested in...
Lupin reported a sharp decline in its fourth quarter profits, dented by heightened price pressure and competition in the US for its key products. The management sees a ‘challenging’ 2018, but underscored the strength of the firm’s ANDA pipeline and enhanced investments in the biosimilars, inhalation and injectables space.
The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.
India’s biggest drug-maker, Sun Pharmaceutical Industries Ltd., has reported a more than tripling of its quarterly profit thanks to US sales of a generic version of Novartis AG’s leukemia blockbuster Gleevec. But now its 180-day sales exclusivity window has closed and generic rivals are launching in the US market, pushing prices down.